Correction: Retrospective Study on the Use of Brodalumab for Atopic Dermatitis Management: Real-World Insights

• by Nikolaos Stavropoulos, Daniel Myszkowski, Dennis Braß, Vasileios Dervenis, Effimia Poungoura, Eggert Stockfleth

• February 6, 2026

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

• by Julia Alicja Lewandowska, Agnieszka Owczarczyk–Saczonek

• May 19, 2026

Atopic Dermatitis Treatment Targets Defined

Consensus definitions for disease control in atopic dermatitis aim to standardize clinical trial end points and support treat-to-target strategies.

• by Kerri Miller

• April 15, 2026

• 5 min

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial

• by Melinda Gooderham, Christopher G. Bunick, JiaDe Yu, Douglas Maslin, Shannon K. R. Schneider, Marie Louise Østerdal, Anders Søhoel, Daniel Elenius Madsen, Lawrence F. Eichenfield

• May 17, 2026